Biologics and Biosimilars Market Report

China Biologics and Biosimilars Industry Market Research Report 2023-2029

  • POSTDATE：Sep 10, 2023
  • PAGES：144
  • REPORT CODE：GMM1787521
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • A biologic is a medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilars are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodies drugs production by bio-engineered technology, but does not include a vaccine.

    Most of biologics manufacturer are concentrated in US, Germany,UK and other developed countries. But in biosimilars industry the situation is different, manufacturer in developing countries play a very important role.Through the research we tend to believe that the growth of biologics industry maybe slow but high profits during the period of patent may attractive. As to biosimilars, now is a changce for newcomers and they will greatly change the industry.

    This report elaborates on the current development of the Biologics and Biosimilars industry thoroughly based on the international market dynamics and China's market situation.

    For a start, the report provides an in-depth analysis of the current market situation through three different aspects - by region, by type and by application, which includes market distribution of different types and applications, import and export analysis of major regions, development trends of different types of products in each region, market opportunities and market restrains of different applications.

    Secondly, this report lists the major players in the industry, displaying their market positions and strengths and weaknesses of their products, picturing the current competitive situation of the whole market. 

    Last but not least, the report analyzes and predicts the investment prospects and risks in the industry on the basis of industry data, combined with experts' opinions and suggestions.

    By Player:

    • Roche

    • Johnson & Johnson

    • Pfizer

    • 3sbio

    • Amgen

    • Novartis

    • Ganlee

    • Eli Lilly

    • Biotech

    • AbbVie

    • Sanofi-Aventis

    • Novo Nordisk

    • CP Guojian

    • Changchun High Tech

    • Merck

    By Type:

    • Monoclonal Antibodies

    • Erythropoietin

    • Insulin

    • Interferon

    • Vaccines

    • Other

    By Application:

    • Diabetes

    • Tumor

    • Other

    • Hemophilia

    • Cardiovascular

    By Research Region:

    • North China

    • Central China

    • South China

    • East China

    • Northeast China

    • Southwest China

    • Northwest China

  • TABLE OF CONTENT

    Chapter 1 China Biologics and Biosimilars Market Overview 2018-2029

    • 1.1 China Biologics and Biosimilars Industry Development Overview

    • 1.2 China Biologics and Biosimilars Industry Development History

    • 1.3 China Biologics and Biosimilars Industry Market Size (2018-2029)

    • 1.4 China Biologics and Biosimilars Market Analysis by Type from Production Side

      • 1.4.1 China Biologics and Biosimilars Production Volume, Production Value and Growth Rate of Monoclonal Antibodies (2018-2029)

      • 1.4.2 China Biologics and Biosimilars Production Volume, Production Value and Growth Rate of Erythropoietin (2018-2029)

      • 1.4.3 China Biologics and Biosimilars Production Volume, Production Value and Growth Rate of Insulin (2018-2029)

      • 1.4.4 China Biologics and Biosimilars Production Volume, Production Value and Growth Rate of Interferon (2018-2029)

      • 1.4.5 China Biologics and Biosimilars Production Volume, Production Value and Growth Rate of Vaccines (2018-2029)

      • 1.4.6 China Biologics and Biosimilars Production Volume, Production Value and Growth Rate of Other (2018-2029)

    • 1.5 China Biologics and Biosimilars Market Analysis by Application from Consumption End

      • 1.5.1 China Biologics and Biosimilars Sales Volume, Sales Value and Growth Rate of Diabetes (2018-2029)

      • 1.5.2 China Biologics and Biosimilars Sales Volume, Sales Value and Growth Rate of Tumor (2018-2029)

      • 1.5.3 China Biologics and Biosimilars Sales Volume, Sales Value and Growth Rate of Other (2018-2029)

      • 1.5.4 China Biologics and Biosimilars Sales Volume, Sales Value and Growth Rate of Hemophilia (2018-2029)

      • 1.5.5 China Biologics and Biosimilars Sales Volume, Sales Value and Growth Rate of Cardiovascular (2018-2029)

    • 1.6 China Biologics and Biosimilars Market Analysis by Region

      • 1.6.1 North China Biologics and Biosimilars Market Size and Growth Rate from 2018-2029

      • 1.6.2 Central China Biologics and Biosimilars Market Size and Growth Rate from 2018-2029

      • 1.6.3 South China Biologics and Biosimilars Market Size and Growth Rate from 2018-2029

      • 1.6.4 East China Biologics and Biosimilars Market Size and Growth Rate from 2018-2029

      • 1.6.5 Northeast China Biologics and Biosimilars Market Size and Growth Rate from 2018-2029

      • 1.6.6 Southwest China Biologics and Biosimilars Market Size and Growth Rate from 2018-2029

      • 1.6.7 Northwest China Biologics and Biosimilars Market Size and Growth Rate from 2018-2029

    Chapter 2 China Biologics and Biosimilars Industry Development Environment

    • 2.1 Industry Development Environment Analysis

      • 2.1.1 Industry Technological Progress Analysis

      • 2.1.2 Industrial Organizational Innovation Analysis

      • 2.1.3 Changes in Social Habits

      • 2.1.4 Alterations in Government Policies

      • 2.1.5 Impact of Economic Globalization

    • 2.2 Domestic and Foreign Industry Competition Analysis

      • 2.2.1 Comparative Analysis on Biologics and Biosimilars Market Status and Competition at home and abroad in 2023

      • 2.2.2 China Biologics and Biosimilars Market Status and Competition Analysis in 2023

      • 2.2.3 China Biologics and Biosimilars Market Concentration Analysis in 2023

    • 2.3 Problems and Countermeasures in the development of China Biologics and Biosimilars Industry

      • 2.3.1 Industry Development Constraints

      • 2.3.2 Industry Development Considerations

      • 2.3.3 Suggestions on Industry Development Measures

      • 2.3.4 Development Strategies for SMEs

    • 2.4 Influence of COVID-19 Outbreak on Biologics and Biosimilars Industry Development

    Chapter 3 Biologics and BiosimilarsIndustry Chain Analysis

    • 3.1 Biologics and Biosimilars Industry Chain

    • 3.2 Biologics and Biosimilars Upstream Industry Analysis

      • 3.2.1 Upstream Industry Development Status

      • 3.2.2 Upstream Industry Development Forecast

      • 3.2.3 Impact of Upstream Industry on the Biologics and Biosimilars Market

    • 3.3 Biologics and Biosimilars Downstream Industry Analysis

      • 3.3.1 Downstream Industry Development Status

      • 3.3.2 Downstream Industry Development Forecast

      • 3.3.3 Impact of Downstream Industry on the Biologics and Biosimilars Market

    Chapter 4 China Biologics and Biosimilars Market, by Type

    • 4.1 China Biologics and Biosimilars Market Trend, by Type

    • 4.2 Product Types of Major Suppliers

    • 4.3 Competitive Landscape of Major Types

    • 4.4 China Biologics and Biosimilars Total Production Volume and Growth Rate from Production Side

    • 4.5 China Biologics and Biosimilars Production Volume and Growth Rate, by Type

      • 4.5.1 China Biologics and Biosimilars Production Volume and Growth Rate of Monoclonal Antibodies

      • 4.5.2 China Biologics and Biosimilars Production Volume and Growth Rate of Erythropoietin

      • 4.5.3 China Biologics and Biosimilars Production Volume and Growth Rate of Insulin

      • 4.5.4 China Biologics and Biosimilars Production Volume and Growth Rate of Interferon

      • 4.5.5 China Biologics and Biosimilars Production Volume and Growth Rate of Vaccines

      • 4.5.6 China Biologics and Biosimilars Production Volume and Growth Rate of Other

    Chapter 5 China Biologics and Biosimilars Market, by Application

    • 5.1 Downstream Market Overview

    • 5.2 Competitive Landscape of Major Applications

    • 5.3 Market Potential Analysis, by Application

    • 5.4 China Biologics and Biosimilars Total Market Size and Growth Rate from Consumption End

    • 5.5 China Biologics and Biosimilars Market Size and Growth Rate, by Application

      • 5.5.1 China Biologics and Biosimilars Market Size and Growth Rate of Diabetes

      • 5.5.2 China Biologics and Biosimilars Market Size and Growth Rate of Tumor

      • 5.5.3 China Biologics and Biosimilars Market Size and Growth Rate of Other

      • 5.5.4 China Biologics and Biosimilars Market Size and Growth Rate of Hemophilia

      • 5.5.5 China Biologics and Biosimilars Market Size and Growth Rate of Cardiovascular

    Chapter 6 China Biologics and Biosimilars Market, by Region

    • 6.1 China Biologics and Biosimilars Production Volume and Production Value, by Region

    • 6.2 China Biologics and Biosimilars Sales Volume and Sales Value, by Region

    Chapter 7 North China Biologics and Biosimilars Market Analysis

    • 7.1 North China Biologics and Biosimilars Market, by Type

    • 7.2 North China Biologics and Biosimilars Market, by Application

    Chapter 8 Central China Biologics and Biosimilars Market Analysis

    • 8.1 Central China Biologics and Biosimilars Market, by Type

    • 8.2 Central China Biologics and Biosimilars Market, by Application

    Chapter 9 South China Biologics and Biosimilars Market Analysis

    • 9.1 South China Biologics and Biosimilars Market, by Type

    • 9.2 South China Biologics and Biosimilars Market, by Application

    Chapter 10 East China Biologics and Biosimilars Market Analysis

    • 10.1 East China Biologics and Biosimilars Market, by Type

    • 10.2 East China Biologics and Biosimilars Market, by Application

    Chapter 11 Northeast China Biologics and Biosimilars Market Analysis

    • 11.1 Northeast China Biologics and Biosimilars Market, by Type

    • 11.2 Northeast China Biologics and Biosimilars Market, by Application

    Chapter 12 Southwest China Biologics and Biosimilars Market Analysis

    • 12.1 Southwest China Biologics and Biosimilars Market, by Type

    • 12.2 Southwest China Biologics and Biosimilars Market, by Application

    Chapter 13 Northwest China Biologics and Biosimilars Market Analysis

    • 13.1 Northwest China Biologics and Biosimilars Market, by Type

    • 13.2 Northwest China Biologics and Biosimilars Market, by Application

    Chapter 14 Company Profiles

      • 14.1 Roche

        • 14.1.1 Roche Company Profile

        • 14.1.2 Roche Biologics and Biosimilars Market Performance

        • 14.1.3 Product&Service Introduction

      • 14.2 Johnson & Johnson

        • 14.2.1 Johnson & Johnson Company Profile

        • 14.2.2 Johnson & Johnson Biologics and Biosimilars Market Performance

        • 14.2.3 Product&Service Introduction

      • 14.3 Pfizer

        • 14.3.1 Pfizer Company Profile

        • 14.3.2 Pfizer Biologics and Biosimilars Market Performance

        • 14.3.3 Product&Service Introduction

      • 14.4 3sbio

        • 14.4.1 3sbio Company Profile

        • 14.4.2 3sbio Biologics and Biosimilars Market Performance

        • 14.4.3 Product&Service Introduction

      • 14.5 Amgen

        • 14.5.1 Amgen Company Profile

        • 14.5.2 Amgen Biologics and Biosimilars Market Performance

        • 14.5.3 Product&Service Introduction

      • 14.6 Novartis

        • 14.6.1 Novartis Company Profile

        • 14.6.2 Novartis Biologics and Biosimilars Market Performance

        • 14.6.3 Product&Service Introduction

      • 14.7 Ganlee

        • 14.7.1 Ganlee Company Profile

        • 14.7.2 Ganlee Biologics and Biosimilars Market Performance

        • 14.7.3 Product&Service Introduction

      • 14.8 Eli Lilly

        • 14.8.1 Eli Lilly Company Profile

        • 14.8.2 Eli Lilly Biologics and Biosimilars Market Performance

        • 14.8.3 Product&Service Introduction

      • 14.9 Biotech

        • 14.9.1 Biotech Company Profile

        • 14.9.2 Biotech Biologics and Biosimilars Market Performance

        • 14.9.3 Product&Service Introduction

      • 14.10 AbbVie

        • 14.10.1 AbbVie Company Profile

        • 14.10.2 AbbVie Biologics and Biosimilars Market Performance

        • 14.10.3 Product&Service Introduction

      • 14.11 Sanofi-Aventis

        • 14.11.1 Sanofi-Aventis Company Profile

        • 14.11.2 Sanofi-Aventis Biologics and Biosimilars Market Performance

        • 14.11.3 Product&Service Introduction

      • 14.12 Novo Nordisk

        • 14.12.1 Novo Nordisk Company Profile

        • 14.12.2 Novo Nordisk Biologics and Biosimilars Market Performance

        • 14.12.3 Product&Service Introduction

      • 14.13 CP Guojian

        • 14.13.1 CP Guojian Company Profile

        • 14.13.2 CP Guojian Biologics and Biosimilars Market Performance

        • 14.13.3 Product&Service Introduction

      • 14.14 Changchun High Tech

        • 14.14.1 Changchun High Tech Company Profile

        • 14.14.2 Changchun High Tech Biologics and Biosimilars Market Performance

        • 14.14.3 Product&Service Introduction

      • 14.15 Merck

        • 14.15.1 Merck Company Profile

        • 14.15.2 Merck Biologics and Biosimilars Market Performance

        • 14.15.3 Product&Service Introduction

    Chapter 15 Research Conclusions and Investment Suggestions

    • 15.1 Biologics and Biosimilars Industry Research Conclusions

    • 15.2 Biologics and Biosimilars Industry Investment Suggestions

      • 15.2.1 Suggestions on Industry Development Strategy

      • 15.2.2 Suggestions on Industry Investment Direction

      • 15.2.3 Suggestions on Industry Investment Strategy


    List of Tables and Figures

    • Figure China Biologics and Biosimilars Industry Market Size (2018-2029)

    • Figure China Biologics and Biosimilars Production Volume, Production Value and Growth Rate of Monoclonal Antibodies (2018-2029)

    • Figure China Biologics and Biosimilars Production Volume, Production Value and Growth Rate of Erythropoietin (2018-2029)

    • Figure China Biologics and Biosimilars Production Volume, Production Value and Growth Rate of Insulin (2018-2029)

    • Figure China Biologics and Biosimilars Production Volume, Production Value and Growth Rate of Interferon (2018-2029)

    • Figure China Biologics and Biosimilars Production Volume, Production Value and Growth Rate of Vaccines (2018-2029)

    • Figure China Biologics and Biosimilars Production Volume, Production Value and Growth Rate of Other (2018-2029)

    • Figure China Biologics and Biosimilars Sales Volume, Sales Value and Growth Rate of Diabetes (2018-2029)

    • Figure China Biologics and Biosimilars Sales Volume, Sales Value and Growth Rate of Tumor (2018-2029)

    • Figure China Biologics and Biosimilars Sales Volume, Sales Value and Growth Rate of Other (2018-2029)

    • Figure China Biologics and Biosimilars Sales Volume, Sales Value and Growth Rate of Hemophilia (2018-2029)

    • Figure China Biologics and Biosimilars Sales Volume, Sales Value and Growth Rate of Cardiovascular (2018-2029)

    • Figure North China Biologics and Biosimilars Market Size and Growth Rate from 2018-2029

    • Figure Central China Biologics and Biosimilars Market Size and Growth Rate from 2018-2029

    • Figure South China Biologics and Biosimilars Market Size and Growth Rate from 2018-2029

    • Figure East China Biologics and Biosimilars Market Size and Growth Rate from 2018-2029

    • Figure Northeast China Biologics and Biosimilars Market Size and Growth Rate from 2018-2029

    • Figure Southwest China Biologics and Biosimilars Market Size and Growth Rate from 2018-2029

    • Figure Northwest China Biologics and Biosimilars Market Size and Growth Rate from 2018-2029

    • Figure Biologics and Biosimilars Industry Chain

    • Table Product Types of Major Suppliers in 2023

    • Figure China Biologics and Biosimilars Market Share by Type in 2018

    • Figure China Biologics and Biosimilars Market Share by Type in 2023

    • Figure China Biologics and Biosimilars Total Production Volume and Growth Rate from Production Side (2018-2023)

    • Figure China Biologics and Biosimilars Production Volume and Growth Rate of Monoclonal Antibodies (2018-2023)

    • Figure China Biologics and Biosimilars Production Volume and Growth Rate of Erythropoietin (2018-2023)

    • Figure China Biologics and Biosimilars Production Volume and Growth Rate of Insulin (2018-2023)

    • Figure China Biologics and Biosimilars Production Volume and Growth Rate of Interferon (2018-2023)

    • Figure China Biologics and Biosimilars Production Volume and Growth Rate of Vaccines (2018-2023)

    • Figure China Biologics and Biosimilars Production Volume and Growth Rate of Other (2018-2023)

    • Figure China Biologics and Biosimilars Market Share by Application in 2018

    • Figure China Biologics and Biosimilars Market Share by Application in 2023

    • Figure China Biologics and Biosimilars Total Market Size and Growth Rate from Consumption End

    • Figure China Biologics and Biosimilars Market Size and Growth Rate of Diabetes (2018-2023)

    • Figure China Biologics and Biosimilars Market Size and Growth Rate of Tumor (2018-2023)

    • Figure China Biologics and Biosimilars Market Size and Growth Rate of Other (2018-2023)

    • Figure China Biologics and Biosimilars Market Size and Growth Rate of Hemophilia (2018-2023)

    • Figure China Biologics and Biosimilars Market Size and Growth Rate of Cardiovascular (2018-2023)

    • Table China Biologics and Biosimilars Production Volume by Region (2018-2023)

    • Table China Biologics and Biosimilars Production Volume Share by Region (2018-2023)

    • Figure China Biologics and Biosimilars Production Volume Share by Region (2018-2023)

    • Table China Biologics and Biosimilars Production Value by Region (2018-2023)

    • Table China Biologics and Biosimilars Production Value Share by Region (2018-2023)

    • Figure China Biologics and Biosimilars Production Value Share by Region (2018-2023)

    • Table China Biologics and Biosimilars Sales Volume by Region (2018-2023)

    • Table China Biologics and Biosimilars Sales Volume Share by Region (2018-2023)

    • Figure China Biologics and Biosimilars Sales Volume Share by Region (2018-2023)

    • Table China Biologics and Biosimilars Sales Value by Region (2018-2023)

    • Table China Biologics and Biosimilars Sales Value Share by Region (2018-2023)

    • Figure China Biologics and Biosimilars Sales Value Share by Region (2018-2023)

    • Table North China Biologics and Biosimilars Production Volume by Type (2018-2023)

    • Table North China Biologics and Biosimilars Production Volume Share by Type (2018-2023)

    • Figure North China Biologics and Biosimilars Production Volume Share by Type (2018-2023)

    • Table North China Biologics and Biosimilars Sales Volume by Application (2018-2023)

    • Table North China Biologics and Biosimilars Sales Volume Share by Application (2018-2023)

    • Figure North China Biologics and Biosimilars Sales Volume Share by Application (2018-2023)

    • Table Central China Biologics and Biosimilars Production Volume by Type (2018-2023)

    • Table Central China Biologics and Biosimilars Production Volume Share by Type (2018-2023)

    • Figure Central China Biologics and Biosimilars Production Volume Share by Type (2018-2023)

    • Table Central China Biologics and Biosimilars Sales Volume by Application (2018-2023)

    • Table Central China Biologics and Biosimilars Sales Volume Share by Application (2018-2023)

    • Figure Central China Biologics and Biosimilars Sales Volume Share by Application (2018-2023)

    • Table South China Biologics and Biosimilars Production Volume by Type (2018-2023)

    • Table South China Biologics and Biosimilars Production Volume Share by Type (2018-2023)

    • Figure South China Biologics and Biosimilars Production Volume Share by Type (2018-2023)

    • Table South China Biologics and Biosimilars Sales Volume by Application (2018-2023)

    • Table South China Biologics and Biosimilars Sales Volume Share by Application (2018-2023)

    • Figure South China Biologics and Biosimilars Sales Volume Share by Application (2018-2023)

    • Table East China Biologics and Biosimilars Production Volume by Type (2018-2023)

    • Table East China Biologics and Biosimilars Production Volume Share by Type (2018-2023)

    • Figure East China Biologics and Biosimilars Production Volume Share by Type (2018-2023)

    • Table East China Biologics and Biosimilars Sales Volume by Application (2018-2023)

    • Table East China Biologics and Biosimilars Sales Volume Share by Application (2018-2023)

    • Figure East China Biologics and Biosimilars Sales Volume Share by Application (2018-2023)

    • Table Northeast China Biologics and Biosimilars Production Volume by Type (2018-2023)

    • Table Northeast China Biologics and Biosimilars Production Volume Share by Type (2018-2023)

    • Figure Northeast China Biologics and Biosimilars Production Volume Share by Type (2018-2023)

    • Table Northeast China Biologics and Biosimilars Sales Volume by Application (2018-2023)

    • Table Northeast China Biologics and Biosimilars Sales Volume Share by Application (2018-2023)

    • Figure Northeast China Biologics and Biosimilars Sales Volume Share by Application (2018-2023)

    • Table Southwest China Biologics and Biosimilars Production Volume by Type (2018-2023)

    • Table Southwest China Biologics and Biosimilars Production Volume Share by Type (2018-2023)

    • Figure Southwest China Biologics and Biosimilars Production Volume Share by Type (2018-2023)

    • Table Southwest China Biologics and Biosimilars Sales Volume by Application (2018-2023)

    • Table Southwest China Biologics and Biosimilars Sales Volume Share by Application (2018-2023)

    • Figure Southwest China Biologics and Biosimilars Sales Volume Share by Application (2018-2023)

    • Table Northwest China Biologics and Biosimilars Production Volume by Type (2018-2023)

    • Table Northwest China Biologics and Biosimilars Production Volume Share by Type (2018-2023)

    • Figure Northwest China Biologics and Biosimilars Production Volume Share by Type (2018-2023)

    • Table Northwest China Biologics and Biosimilars Sales Volume by Application (2018-2023)

    • Table Northwest China Biologics and Biosimilars Sales Volume Share by Application (2018-2023)

    • Figure Northwest China Biologics and Biosimilars Sales Volume Share by Application (2018-2023)

    • Table Roche Company Profile

    • Table Roche Biologics and Biosimilars Revenue, Price and Gross (2018-2023)

    • Table Johnson & Johnson Company Profile

    • Table Johnson & Johnson Biologics and Biosimilars Revenue, Price and Gross (2018-2023)

    • Table Pfizer Company Profile

    • Table Pfizer Biologics and Biosimilars Revenue, Price and Gross (2018-2023)

    • Table 3sbio Company Profile

    • Table 3sbio Biologics and Biosimilars Revenue, Price and Gross (2018-2023)

    • Table Amgen Company Profile

    • Table Amgen Biologics and Biosimilars Revenue, Price and Gross (2018-2023)

    • Table Novartis Company Profile

    • Table Novartis Biologics and Biosimilars Revenue, Price and Gross (2018-2023)

    • Table Ganlee Company Profile

    • Table Ganlee Biologics and Biosimilars Revenue, Price and Gross (2018-2023)

    • Table Eli Lilly Company Profile

    • Table Eli Lilly Biologics and Biosimilars Revenue, Price and Gross (2018-2023)

    • Table Biotech Company Profile

    • Table Biotech Biologics and Biosimilars Revenue, Price and Gross (2018-2023)

    • Table AbbVie Company Profile

    • Table AbbVie Biologics and Biosimilars Revenue, Price and Gross (2018-2023)

    • Table Sanofi-Aventis Company Profile

    • Table Sanofi-Aventis Biologics and Biosimilars Revenue, Price and Gross (2018-2023)

    • Table Novo Nordisk Company Profile

    • Table Novo Nordisk Biologics and Biosimilars Revenue, Price and Gross (2018-2023)

    • Table CP Guojian Company Profile

    • Table CP Guojian Biologics and Biosimilars Revenue, Price and Gross (2018-2023)

    • Table Changchun High Tech Company Profile

    • Table Changchun High Tech Biologics and Biosimilars Revenue, Price and Gross (2018-2023)

    • Table Merck Company Profile

    • Table Merck Biologics and Biosimilars Revenue, Price and Gross (2018-2023)


Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US